clinical-trial is the sole category represented across all 1 tracked stories. Vinita Gupta is most often covered alongside Dr. Robert Pierce, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Vinita Gupta, all published on July 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Vinita Gupta
clinical-trial is the sole category represented across all 1 tracked stories. Vinita Gupta is most often covered alongside Dr. Robert Pierce, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Vinita Gupta, all published on July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Vinita Gupta. Shared-story counts are live from our verified record — not editorial picks.
Lupin’s oncology pipeline yields a new standalone startup, Kaveri Therapeutics, built around PRMT5 inhibitor LNP7457 and SOS1 inhibitor LNP8701. Both compounds showed encouraging clinical data at ASCO 2025 and 2026, and the biotech will now seek external funding to advance global trials.
Vinita Gupta is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.